JUNSHI BIO (01877): First patient dosed in Phase III clinical trial of JS203 combined with chemotherapy for the treatment of diffuse large B-cell lymphoma
Junshi Biosciences (01877) announced that the first patient has been dosed in a randomized, open-label, multicenter Phase III clinical study of the company's product, a recombinant humanized anti-CD20 and CD3 bispecific antibody (code: JS203), in combination with chemotherapy versus rituximab in combination with chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This study is the first registrational clinical study of JS203.
JUNSHI BIO (01877) announced that the first patient has been dosed in the company's randomized, open-label, multicenter Phase III clinical study of its product, a recombinant humanized anti-CD20 and CD3 bispecific antibody (code: JS203), in combination with chemotherapy versus rituximab in combination with chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This study is the first registrational clinical study of JS203.
Related Articles
LIANLIAN (02598) plans to contribute RMB 200 million to co-establish a fund, focusing on semiconductors, AI, and advanced manufacturing.
DYNAGREEN ENV (01330) will distribute an interim dividend of RMB 0.11 per share on December 11.
US Stock Market Move | Telecom tower operators rise collectively; Crown Castle Inc. (CCI.US) surges nearly 14%
LIANLIAN (02598) plans to contribute RMB 200 million to co-establish a fund, focusing on semiconductors, AI, and advanced manufacturing.
DYNAGREEN ENV (01330) will distribute an interim dividend of RMB 0.11 per share on December 11.
US Stock Market Move | Telecom tower operators rise collectively; Crown Castle Inc. (CCI.US) surges nearly 14%
